Anika Therapeutics, Inc. (ANIK) stock intrinsic value fair value estimate & owner earnings analysis

Anika Therapeutics manufactures hyaluronic-acid (HA) products at its plant in Bedford, Massachusetts. Its largest products are the knee osteoarthritis injections Monovisc and Orthovisc, which Johnson & Johnson MedTech markets exclusively in the United States; J&J MedTech accounted for 50% of 2025 revenue. Anika also markets Cingal (an HA-plus-steroid injection that is CE marked and sold outside the U.S. but not approved in the U.S.), the Integrity rotator-cuff implant, Tactoset bone substitute, Hyalofast cartilage scaffold (outside the U.S. only), and legacy veterinary, ophthalmic and surgical HA products. The 2020 acquisitions of Arthrosurface and Parcus Medical were sold off in October 2024 and March 2025 at large losses, so the company today is the HA business it was before 2020. How we measured earnings. We measure the cash the business generates for its owners: operating cash flow, with working-capital swings removed, with stock compensation charged as a real cost, with the capital spending needed to maintain the plant deducted, and with the routine inventory write-downs that run through the cash-flow statement charged as a cost. We also strip out the cash results of the divested Arthrosurface and Parcus businesses so that recent years describe only the business that remains. On that basis the continuing business produced about $6.4 million in 2022, $5.0 million in 2023, a shortfall of $5.6 million in 2024 and a shortfall of $12.0 million in 2025, roughly $0.43, $0.34, -$0.38 and -$0.84 per share. Before the acquisitions, from 2016 to 2019, the same measure ran between $1.23 and $2.26 per share. That earlier level is not today's business: the J&J pricing reset in 2025 alone cut revenue by $10.0 million, and stock compensation of about $10.1 million in 2025 compares with $3.4 million in 2016 and $5.8 million in 2017. What changed in 2025 and 2026. Revenue fell 6% to $112.8 million in 2025 because J&J MedTech revenue dropped $12.6 million, $10.0 million of it from lower pricing. The company's own channel, which includes international osteoarthritis products, Integrity and Hyalofast, grew from $36.1 million in 2023 to $42.1 million in 2024 and $48.4 million in 2025. In the first half of 2026 revenue rose to $62.2 million from $54.4 million and the second quarter showed a $3.3 million profit, but stock compensation rose to $8.5 million for the half and inventories grew by about $11.4 million, so operating cash flow was negative $5.5 million. Cash fell from $57.5 million at the end of 2025 to $38.4 million at June 30, 2026, partly from $9.5 million of share repurchases. We estimate owner earnings for the half at a shortfall of roughly $2 million. In October 2025 J&J MedTech extended its exclusive Monovisc agreement through December 2031; the Orthovisc agreement runs through December 2028 and is renewable at J&J's option. Balance sheet. Anika has no borrowings; its $75 million Bank of America revolving line was undrawn at the end of 2025. We count $28.4 million of the June 2026 cash as surplus to operations, holding back about $10 million as working cash. In the base and bull cases we add about $4.0 million for the $7.0 million face-value, non-interest-bearing ten-year note received for Arthrosurface (carried at $5.6 million), whose repayment depends on that business; the bear case gives the note no value. Growth credited. Only the commercial channel's demonstrated three-year growth and the 2022-2025 decline in stock compensation are treated as evidence of improvement, and only partly. Cingal U.S. approval (a bioequivalence study is under way) and Hyalofast U.S. approval are not credited in any case: Hyalofast missed its co-primary endpoints in July 2025 and the FDA issued a deficiency letter in January 2026 covering manufacturing and statistical questions. Management's estimate of a roughly $1 billion U.S. market for Cingal is not used. Base case. In 2025 owner earnings fell from -$5.6 million to -$12.0 million; our base case starts year one better than that, at about -$4 million, only because the first-half 2026 filing already shows a shortfall of roughly $2 million for the half on higher revenue. From there owner earnings improve to about -$2 million, -$1 million and breakeven, then about $1 million a year from year five through year ten as commercial-channel growth offsets continued OEM price pressure. After year ten we fade that $1 million to zero over another ten years, because the J&J agreements run only to 2028 and 2031 and nothing beyond that is contracted. The operating business is worth about -$0.3 million; with $32.4 million of surplus cash and the note, the equity is worth about $32.1 million, or $2.34 per share. In plain terms, in our base case the shares are worth roughly their cash, because the business itself is close to breaking even. Bear case. We use the 2025 episode, when a J&J pricing reset removed $10.0 million of revenue in one year, as the named downturn, and assume it repeats when the Orthovisc agreement comes up for renewal in 2028, with no U.S. approval for Cingal or Hyalofast. Owner earnings run about -$9 million in each of the first two years, -$7 million, -$4 million and -$2 million, then about -$1 million a year to year ten, with no value beyond that. The operating business is worth about -$30.2 million against $28.4 million of surplus cash, so the company appears to be worth about $1.8 million less than nothing, or -$0.13 per share: the cash would be largely consumed by losses. With no debt there is no refinancing risk, so the downside is erosion of the cash rather than a lender-driven loss. Bull case. The first-half 2026 revenue growth holds, the commercial channel keeps growing at its 2023-2025 pace, OEM pricing stabilizes and stock compensation returns toward 2025 levels. Owner earnings move from about -$1 million in year one to $2 million, $4 million, $5.5 million and $6.5 million, then about $7 million a year (about $0.51 per share, still below the 2016-2019 range) through year ten, fading to zero over the following ten years. The business is worth about $51.1 million plus $32.4 million of surplus cash and the note, about $83.5 million or $6.09 per share. Even this case credits no new U.S. approvals. The previous figures for this company are not comparable with these and should not be read as a change in the business. What did change in the business since then: cash fell by about $19 million in the first half of 2026, inventories built sharply, and stock compensation rose. Margin-of-safety price. Confidence in the earnings level is low: the continuing business has swung from about +$6 million to -$12 million in four years, half its revenue depends on one partner that cut prices in 2025, and the two pipeline products that could change the picture both face unresolved FDA questions. The worst plausible outcome no case fully models is J&J declining to renew Orthovisc in 2028 or switching suppliers, which would remove a large part of the OEM channel; the structure would survive because there is no debt, but the cash would be the only thing left. If we are wrong about the 2026 improvement and losses stay near 2025's $12 million a year, roughly two and a half years of losses would consume the surplus cash. While waiting, the business currently produces no owner earnings to pay shareholders, and recent share repurchases have been funded from cash rather than earnings. The margin-of-safety price is $1.25 per share, below the roughly $2.07 per share of surplus cash, so that most of the price is backed by cash even after two to three years of base-case losses. The price assumes a three-to-five-year holding period; from $1.25 the base case implies roughly 31% a year over three years and roughly 20% a year over five, while the bear case implies a loss. That bear-case risk is why the price also depends on the business condition stated with it: two consecutive quarters of positive operating cash flow without growth in inventories, with cash at or above $35 million.